APA (7th ed.) Citation

T, S., S, T., K, M., C, J., F, A., C, B., . . . H, F. (2026). Development and validation of a tumor-derived CXCL1 qPCR assay to support patient selection for anti-CXCL1 therapeutics in bladder cancer. Experimental and molecular pathology, 146, 105039. https://doi.org/10.1016/j.yexmp.2026.105039

Chicago Style (17th ed.) Citation

T, Sakatani, et al. "Development and Validation of a Tumor-derived CXCL1 QPCR Assay to Support Patient Selection for Anti-CXCL1 Therapeutics in Bladder Cancer." Experimental and Molecular Pathology 146 (2026): 105039. https://doi.org/10.1016/j.yexmp.2026.105039.

MLA (9th ed.) Citation

T, Sakatani, et al. "Development and Validation of a Tumor-derived CXCL1 QPCR Assay to Support Patient Selection for Anti-CXCL1 Therapeutics in Bladder Cancer." Experimental and Molecular Pathology, vol. 146, 2026, p. 105039, https://doi.org/10.1016/j.yexmp.2026.105039.